Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Ahsan Rizwan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, BeiGene USA, Inc., San Carlos, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Models, Biological, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible treatment regimens compatible with background chemotherapy and/or reducing infusion visits. A previously developed population pharmacokinetic model was used to simulate pharmacokinetic exposure of the alternative regimens. Regulatory guidance on alternative dosing was used to define pharmacokinetics‐based criteria. Alternative doses were selected by simulation, exposure matching, and comparison to the reference regimen of 200 mg Q3W. Deviations from pharmacokinetics‐based criteria were bridged using appropriate safety and efficacy references and exposure–response analyses. All three alternative dosing regimens produced comparable exposures versus 200 mg Q3W. Although simulated peak serum concentration (C max ) at 300 mg Q4W and 400 mg Q6W was higher versus 200 mg Q3W, this was below the C max of the 5 mg/kg Q3W safety reference. And while the trough serum concentration (C trough ) for 400 mg Q6W was slightly lower versus 200 mg Q3W, it was 10.7% higher than the 2 mg/kg efficacy reference C trough , and therefore, within the concentration range in which a flat exposure–efficacy relationship of tislelizumab has been established. Tislelizumab regimens of 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W are expected to result in similar safety and efficacy as 200 mg Q3W.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Pharmacometrics, BeiGene USA, Inc., San Carlos, California, USA.
- Pharmacometrics, Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
- Scientific Programming, BeiGene (Shanghai) Co., Ltd., Shanghai, China.
- Global Statistics and Data Sciences, BeiGene (Beijing), Co., Ltd., Beijing, China.
- Regulatory Affairs, BeiGene (Canada) ULC, Toronto, Ontario, Canada.
- Product Safety, BeiGene USA, Inc., Ridgefield, New Jersey, USA.
ORCID-Profile: Ahsan Rizwan, Tian Yu, Yuying Gao, Fengyan Xu, Srikumar Sahasranaman, Nageshwar Budha
Zitieren
APA
Rizwan, A., Giovinazzo, H., Yu, T., Gao, Y., Wang, K., Xu, F., Wan, Y., Wang, J., Sahasranaman, S., Campbell, M., Schnell, P., Abdrashitov, R., Hanley, W. D., & Budha, N. (2025). Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach. Clinical and Translational Science. https://doi.org/10.1111/cts.70223
Vancouver
Rizwan A, Giovinazzo H, Yu T, Gao Y, Wang K, Xu F, et al. Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach. Clinical and Translational Science. 2025. doi:10.1111/cts.70223
BibTeX
@article{Rizwan2025,
author = {Rizwan, Ahsan and Giovinazzo, Hugh and Yu, Tian and Gao, Yuying and Wang, Kun and Xu, Fengyan and Wan, Ya and Wang, Jun and Sahasranaman, Srikumar and Campbell, Marcia and Schnell, Patrick and Abdrashitov, Ramil and Hanley, William D and Budha, Nageshwar},
title = {Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70223}
}
EUVIMED